ImmunityBio, Inc. (IBRX) Balance Sheet
As of 2026-06-30 (10-Q), ImmunityBio, Inc. (IBRX) reported total assets of $628.5M, total liabilities of $1.7B and shareholders' equity of -$1.0B, according to EquiReason's reading of its SEC filings. Cash and equivalents: $75.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IBRXImmunityBio, Inc.Follow IBRX — free
—
Price chart with a free account
- Market cap
- 8.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | Latest Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 8.1 | 23.9 | 16.8 | 75.8 | 34.9 | 181.1 | 104.6 | 265.5 | 143.4 | 88.3 | 75.7 | |
| Short-term investments | 190.8 | 104.3 | 57.3 | 36.1 | 61.1 | 136.0 | 2.5 | 1.0 | 6.4 | 154.5 | 281.7 | |
| Receivables | — | — | — | — | — | — | — | 0.0 | 2.4 | 42.6 | 53.5 | |
| Inventory | — | — | — | — | — | — | — | 0.0 | 8.3 | 0.9 | 1.9 | |
| Current assets | 205.1 | 132.5 | 88.8 | 55.8 | 111.7 | 334.3 | 140.6 | 294.1 | 184.6 | 314.9 | 439.0 | |
| Total assets | 317.5 | 250.4 | 182.0 | 143.1 | 221.4 | 468.9 | 362.4 | 504.5 | 382.9 | 501.9 | 628.5 | |
| Current liabilities | 12.6 | 20.9 | 27.3 | 11.6 | 68.1 | 369.0 | 500.9 | 58.3 | 54.9 | 61.8 | 76.7 | |
| Short-term debt | — | — | — | — | — | — | — | — | 1.2 | 1.8 | — | |
| Total liabilities | 24.1 | 31.6 | 35.9 | 22.4 | 339.9 | 712.8 | 812.2 | 1,090.4 | 871.1 | 1,001.5 | 1,674.3 | |
| Shareholders' equity | 293.4 | 218.8 | 146.0 | 120.7 | -119.8 | -242.2 | -447.3 | -587.0 | -489.1 | -500.5 | -1,046.6 |
USD millions · SEC XBRL
ImmunityBio, Inc. — questions
- How much cash does ImmunityBio, Inc. have?
- $75.7M in cash and cash equivalents as of 2026-06-30.
- What are ImmunityBio, Inc.'s total assets?
- $628.5M as of 2026-06-30.
- What is ImmunityBio, Inc.'s shareholders' equity?
- -$1.0B as of 2026-06-30.
Every figure on this page comes from ImmunityBio, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.